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Coronary angiography is a critical diagnostic tool for
deﬁning anatomy and guiding therapy in coronary artery
disease. Not surprisingly, it has gained widespread use since
Mason Sones ﬁrst described it over 50 years ago with an
estimated 2 million procedures performed each year in the
United States alone (1). However, there are well-known,
signiﬁcant costs associated with coronary angiography,
both to the patient (given its procedural risks) and to the
healthcare system as a whole. In 2010, a highly publicized
article by Patel et al. (2), in the New England Journal of
Medicine, raised concerns about the potential, indiscriminate
use of coronary angiography given its “low diagnostic yield.”See page 417Utilizing data on nearly 400,000 patients without known
coronary artery disease who had been referred for elective
procedures in the CathPCI Registry, only 38% were found
to have obstructive disease, whereas 39% had little or no
disease (i.e., “normal” coronary arteries). Adding to these
troubling ﬁndings were the observations that a large number
of patients were asymptomatic (w30%) and noninvasive
testing before the procedure did not improve diagnostic
yield.
Ko et al. (3) further explored these issues in an intriguing
report published earlier this year in the Journal of the American
Medical Association in which cross-national comparison data
were used between New York State and Ontario. In this
study, the authors compared 18,114 patients in New York
and 54,933 patients in Ontario who were undergoing elec-
tive coronary angiography (utilizing a government-funded,
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this paper to disclose.obstructive disease in New York was only 30% compared with
45% in Ontario, which is a ﬁnding primarily driven by
a higher rate of referral of low-risk patients in New York.
Using a risk model based on clinical factors and noninvasive
testing, fewer than 1 in 5 patients in New York had greater
than 50% likelihood of an obstructive coronary artery disease
compared with more than 2 in 5 patients in Ontario.
Importantly, no underdetection of patients with surgical
coronary artery disease (left main disease or 3-vessel coronary
artery disease) was noted, despite a historically 50% lower
use of coronary angiography per capita in Ontario. Thus,
a more restricted approach to patient selection for coronary
angiography in Ontario did not appear to miss those with
critical disease.
In this issue of the Journal, Bradley et al. (4) add to this
discussion with a report from the Veterans Affair (VA)
Healthcare System’s Cardiovascular Assessment, Reporting
and Tracking for Cath Labs (CART-CL) program. This
study is important because the VA Healthcare System
represents a large, integrated healthcare delivery system
in the United States where ﬁnancial incentives for per-
forming coronary angiography and medico-legal concerns
may be less than in the private sector. The authors utilized
data from 76 VA cardiac catheterization laboratories
between 2007 and 2010. Of the 22,538 patients who
underwent elective coronary angiography during this time
period, 4,829 had normal coronary arteries (21%) and
11,622 (52%) had obstructive disease. Patients with normal
coronary arteries were more likely to have low Framingham
risk scores and to have undergone a noninvasive test.
To assess hospital-level variation, the hospitals were divided
into quartiles based on the percentage of cases with normal
coronary arteries with quartile 1 having a rate of normal
coronary arteries of 11% and quartile 4 having a rate of 30%.
Patients in quartile 1 were more likely to undergo nonin-
vasive testing, but no consistent trends were noted across
quartiles in patient demographics, cardiovascular risk factors,
Framingham scores, or hospital characteristics.
This work by Bradley et al. (4) is important for several
reasons. First, it suggests a higher referral threshold for
coronary angiography within the VA. Given the possi-
bility of less direct ﬁnancial incentives for testing in an
integrated healthcare delivery system, this ﬁnding may
have implications for Accountable Care Organizations
that will gain traction in the coming years. Second, their
observation of 10-fold variation in hospital rates of
normal coronary arteries is important. Despite ﬁnding
an overall rate of normal coronary arteries that was al-
most one-half of what was reported from the CathPCI
Registry, this inconsistency implies an ongoing need to
improve patient selection across institutions and reminds
us that factors beyond ﬁnancial incentives are playing
a role. Third, this report raises a real concern regarding
studies that compare rates of normal coronary arteries
across healthcare systems that many VA cardiologists will
immediately recognize. Given a higher burden of baseline
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428disease in the VA population, a poor decision to perform
coronary angiography in a veteran (e.g., asymptomatic
and low-risk stress test) may be statistically more likely to
yield obstructive disease than an appropriate decision in
other settings. As even 10% of patients with an acute
coronary syndrome might have nonobstructive disease (5),
we may be right, but for the wrong reasons, or wrong
for the right reasons.
Thus, it remains unclear as to what we (as a clinical
community) are to do collectively with these studies of rates
of normal coronary arteries (and the others that may
potentially follow). Yet, the questions that they raise are
potentially enormous. To what extent do high rates of
coronary arteries indicate poor quality or suggest that we are
performing too many procedures? Do we need to become
more adept at risk stratiﬁcation or do we need more or better
noninvasive testing? How are ﬁnancial incentives driving
these decisions and what other factorsdsuch as medico-
legal concernsdare playing a role in patient selection?
And ﬁnally, what is a reasonable rate of normal coronary
arteries that should be expected for cardiologists, realizing
that 0% is neither possible nor desirable?
Of course, many of these questions deal with the overall
quality of current clinical assessments and noninvasive
testing. These issues were highlighted over 3 decades ago
in the seminal work of Diamond and Forrester (6) with
their application of Bayes’ theorem to coronary angiography.
Results of any clinical ﬁnding or diagnostic test must be
placed into the context of a patient, as their interpretation
inherently depends on the pretest probability of disease.
Diamond and Forrester (6) demonstrated that the probabi-
lity of coronary artery disease may be obtained in large part
through assessment of the patient’s age, sex, and symptoms.
Despite signiﬁcant advancements in noninvasive tests since
that time, it is disappointing that these tests only marginally
improve the diagnostic yield of coronary angiography over
these clinical factors (7).
Despite the clear need to improve our decision-making
process for coronary angiography, it also is important to
acknowledge that some elective procedures will undoubtedly
result in the ﬁnding of normal coronary arteries. So when is
it right for us to be wrong? Is the rate of normal coronary
arteries found in the CathPCI Registry of 39% too high or
perhaps the rate of 21% in the VA population too low? Too
high a rate suggests waste and the danger of unnecessary
procedures, whereas too low a rate implies we may be
causing harm by missing patients appropriately referred for
this diagnostic test. Although the study by Ko et al. (3)
suggests this latter concern may be minimized, it is clear
(even from that study) that we must be able to accept a few
false-positive test results as part of the process. In some
circumstances, there may be great value to a negative study
that identiﬁes normal coronary arteries, given the concerns
many patients have with the possibility of cardiac condi-
tions as a cause of their symptoms. In fact, the value of
any diagnostic test lies not only in its ability to “rulein”disease, but in how it helps clinicians to “ruleout” disease
as well because that also strongly inﬂuences subsequent
management.
We believe many forces will push this debate even further
in the coming years. Rates of normal coronary angiographies
have been discussed as a performance measure for over
a decade now, but there has been little pursuit of it (8).
However, the emerging data highlighted by Patel et al. (2),
Ko et al. (3), and Bradley et al. (4) suggest that a greater
interest will and should be placed on risk stratiﬁcation and
patient selection in the coming years. This is further sup-
ported by the recent publication of appropriate use criteria
(AUC) for coronary angiography. Using rates of normal
coronary arteries may supplement AUC to fully inform us
on how well an entire system is doing in this regard and
ensure the validity in quality comparisons across hospitals.
Bradley et al. (4) eloquently raise these points in their article,
but they also warn us about potential limitations with its
use in isolation. For example, before rates of normal coro-
nary arteries become a performance measure, we clearly need
more empirical work as ranking of hospitals in the VA
Healthcare System was highly sensitive to how “normal” was
deﬁned. In Figure 3 of the article by Bradley et al. (4), the
top hospital ranked by its rate of normal coronary arteries
was approximately 50th by its rate of nonobstructive coro-
nary artery disease.
Although the extent to which the use of rankings and
performance measurement of rates of normal coronary
arteries may inﬂuence clinicians is unclear, it may be
consequential. A prominent example of the real-world
implications of these decisions was recently illustrated. In
a $4 million settlement by a physician and healthcare system
for allegedly performing unnecessary coronary angiography,
it was purported that 75% of patients had “no signiﬁcant
heart blockages” (9). This case is obviously complex and
raised multiple issues, including the improper reading of
nuclear stress tests prior to coronary angiography. Yet, it is
telling that this case is fundamentally different from prior
reports of inappropriate coronary stenting or cardiac surgery
because it involves the claim that a diagnostic test, and not
a therapeutic procedure, was overused. This also raises the
natural question as to whether this logic may be extended to
other diagnostic tests, such as measures of normal rates of
echocardiograms, computed tomography scans, ultrasounds,
and even some expensive laboratory tests.
Improving our understanding of all these issues sur-
rounding rates of normal coronary arteries will be funda-
mental as we move forward in an era of AUC, quality
improvement initiatives, performance measures, and esca-
lating costs. This must be done carefully with recognition
that large differences will exist across the populations that we
serve. This should inﬂuence how these data are collected,
interpreted, and reported. As clinicians, we certainly need to
become better at how we utilize expensive and sometimes
risky tests like coronary angiography. This desire for
improvement, however, must be balanced with the
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429knowledge that there remains an important role for judg-
ment in such decisions. That is we need to hold on to the
right to be wrong.
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